News
Events
Research
Ways to help
About us
Contact Us
DONATE NOW
EVENTS
ANNUAL BALL
CONTACT US
SIGN UP TO NEWSLETTER
Jun 2014
Predicting MS in children
Oct 2014
Three new Incubator Grants announced
Dec 2014
2015 Funding announced
Mar 2015
Investigating new treatment options
Oct 2015
Progress in MS Research Conference
Feb 2016
2016 Round of Funding
Feb 2014
New projects being funded
Feb 2014
Breakthrough study shows great promise

Professor Pender working towards
a new treatment for progressive MS

Professor Michael Pender from the University of Queensland continues to make excellent progress in his research project looking at the role of Epstein Barr Virus (EBV) in MS. Professor Pender’s project is running over three years and is supported by Foundation 5 Million Plus and The Trish MS Research Foundation.

A large body of evidence indicates that infection with EBV has a key role in MS. EBV is the glandular fever virus and exposure is very common, with EBV infecting around 95% of all adults, but over 99% of people with MS. Although it is usually well controlled by a person’s immune system, it is not fully cleared and EBV remains within immune cells in a resting state.

In his research, Professor Pender has shown that people with MS have decreased immunity to EBV which could allow the accumulation of EBV-infected cells in the brain and the subsequent development of MS. This project is investigating specific immune cells involved with the response to EBV infection known as CD8 T cells.

Professor Pender has completed a large amount of work on this project, including showing that the CD8 T cells are deficient in people with MS and that this is due to a reduced number of CD8 memory T cells. These cell types retain a memory of foreign infections that they have ‘seen’ before and can immediately mount a response to clear infected cells. Further work in people at the earliest stages of MS, those with clinically isolated syndrome, showed that these people also had this cellular deficiency – suggesting it may be a cause rather than an outcome of disease processes.  

Most excitingly, this work laid the foundation for an experimental treatment trial in a single person with secondary progressive MS in 2014. The treatment was based on the use of with CD8 cells primed to recognise EBV. The therapy had no adverse effects and the patient showed clinical improvement with reduced disease activity.

This is the first time that this type of therapy, known as ‘adoptive immunotherapy’, has been used to treat MS or any other autoimmune disease. Professor Pender and colleagues are now planning to undertake a phase I clinical trial to test the safety of this therapy in a small group of people.

Future work at the laboratory bench will investigate the relationship between MS and different phases of EBV infection as well as the immune response to EBV infection in people with MS. This detailed characterisation of EBV in MS can only assist with the success of the ongoing clinical studies. We await his further results with great interest.

Trish Foundation & MS Research Australia Working together to find a cure for MS
Copyright © Trish Multiple Sclerosis Research Foundation. All rights reserved.